All In Biotech

Drug Trial Radar · NCT03787602

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve

Last checked: Nov 19, 2026Latest source record: Mar 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

115

Planned (sponsor's estimate)

Start

Mar 19, 2019

Primary completion

Nov 2024

Study completion Aug 2025

Sponsor

Lead sponsor
Kartos Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.

Conditions

  • Merkel Cell Carcinoma

Interventions

  • KRT-232Drug

    KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

  • AvelumabDrug

    Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1 Part 1: To determine the KRT-232 RP2D.Time frame: 10 Weeks
  2. Cohort 1 Part 2: To determine the objective response rate (ORR) in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapyTime frame: 10 Weeks
  3. Cohort 2 Part 1: To determine the KRT-232 RP2D in combination with avelumabTime frame: 28 Days
  4. Cohort 2 Part 2: To determine the objective response rate (ORR) in treatment-naïve subjects with p53WT MCCTime frame: 10 Weeks
  5. Cohort 3: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC are chemotherapy naive and have failed anti-PD-1/PD-L.Time frame: 10 Weeks
  6. Cohort 4: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapy and have had least 1 line of prior chemotherapy.Time frame: 10 Weeks

Locations

51 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Moffitt

    Tampa, Florida · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • Norton Healthcare

    Louisville, Kentucky · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • Mount Sinai Hospital

    New York, New York · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Active not recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • University of Texas MD Anderson

    Houston, Texas · Recruiting

  • Inova Health Care Services

    Fairfax, Virginia · Recruiting

  • Princess Alexandra Hospital Oncology

    Woolloongabba, Australia · Recruiting

  • Centro Catarinense de Pesquisa (CECAP) - Hospital Santa Catarina de Blumenau

    Blumenau, Brazil · Recruiting

  • Instituto Nacional do Cancer

    Brasília, Brazil · Recruiting

  • Centro Intergado de Oncologia

    Curitiba, Brazil · Recruiting

  • Centro de Pesquisa Clinica em Oncologia

    Ijuí, Brazil · Recruiting

  • Clinica De Neoplasias Litoral

    Itajaí, Brazil · Recruiting

  • Hospital Paulistano

    São Paulo, Brazil · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Canada · Recruiting

  • CHU de Bordeaux- Hopital Saint-Andre

    Bordeaux, France · Recruiting

  • AP-HP Universite Paris Saclay

    Gif-sur-Yvette, France · Recruiting

  • CHU de Lille

    Lille, France · Recruiting

  • CHU Lyon-Sud

    Lyon, France · Recruiting

  • Hôpital de la Timone. Aix-Marseille Université

    Marseille, France · Recruiting

  • CHU Montpellier

    Montpellier, France · Recruiting

  • CHU de Nantes

    Nantes, France · Recruiting

  • Hôpital Saint Louis - APHP

    Paris, France · Recruiting

  • CHU de Tours

    Tours, France · Recruiting

  • Vivantes Network for Health Gmb, Neukölln Clinic

    Berlin, Germany · Recruiting

  • Uniklinik Koln

    Cologne, Germany · Recruiting

  • Universitätsklinikum Erlangen

    Erlangen, Germany · Recruiting

  • Universitätsklinikum Essen (AöR)

    Essen, Germany · Recruiting

  • Nationales Centrum für Tumorerkrankungen NCT

    Heidelberg, Germany · Recruiting

  • Universitätsklinik Rostock

    Rostock, Germany · Recruiting

  • Universitats-Hautklinik Tubingen

    Tübingen, Germany · Recruiting

  • Institute for Cancer Research and Treatment

    Candiolo, Italy · Recruiting

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale

    Naples, Italy · Recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.